3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
18
Phase 2
5
Phase NA
4
Phase 1/2
3
Phase 3
2
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
12
Thoracic
2
Genitourinary
2
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Conditions
Ovarian Neoplasms
26
Uterine Cervical Neoplasms
16
Endometrial Neoplasms
14
Fallopian Tube Neoplasms
10
Carcinoma, Ovarian Epithelial
7
Colorectal Neoplasms
6
Peritoneal Neoplasms
5
Neoplasms
5
Uterine Cervical Dysplasia
4
Lung Neoplasms
4
Gestational Trophoblastic Disease
4
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Melanoma
3
Hematologic Neoplasms
3
Endometrial Hyperplasia
3
Urinary Bladder Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Ovarian Cysts
2
Obesity
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Interventions
pertuzumab
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Gallbladder Neoplasms
×
Gynecologic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled